Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a retrospective comparative study

Xinfeng Yao, Dongju Huang, Xiangying Shi, Fangping Xiang, Liu Liu · 2026

Read Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a retrospective comparative study by Xinfeng Yao, Dongju Huang, Xiangying Shi, Fangping Xiang, Liu Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13175792.txt.

Description

Xinfeng Yao and co-authors compare two common diabetes drug classes in real-world care in this 2026 study. Type 2 diabetes keeps growing worldwide, and drug choice shapes long-term health. The two classes work differently: one sheds sugar in urine, the other boosts insulin control.

The retrospective study reviews patients treated over about a year. It compares how well each class lowered blood sugar and how safe each proved. It also hunts for traits that predict a strong response to either class. Real-world records catch effects that tight trials can miss. Doctors choosing a first add-on drug can use the head-to-head picture. Patients gain when that choice starts from evidence.

Catalog record

CREATORXinfeng Yao, Dongju Huang, Xiangying Shi, Fangping Xiang, Liu Liu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE67 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13175792

Browse the full library · About the Tower of Babel